DexCom: The Growth Thesis Still Needs To Be Proven

DexCom faces a pivotal transition as GLP-1 adoption threatens its core insulin-treated diabetes market.

DXCM aims to expand CGM adoption to Type 2 non-insulin patients, but commercial uptake remains unproven despite positive clinical trial results.

At 28x earnings, DXCM's valuation is not demanding, yet offers limited upside given execution risks and the need for evidence of new market penetration.

I assign DXCM a Hold rating, pending clearer signs that expansion into non-insulin patients drives sustainable growth.